RxDoctor Payments Data

Keith Charles, MD

Ophthalmology · Mount Dora, FLNPI 1255334389

Payments from drug & device makers

$193,894in general payments, 2019–2025

Across 72 payments — averaging $2692.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$107K
  • Novartis$51K
  • Oyster Point Pharma, Inc.$31K
  • Glaukos Corporation$4K
  • Alcon$583
  • Dompe US, Inc.$548
  • plus $186 from 7 others

What the payments were for

  • Food & beverage$1,490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$193,894 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$528,226
Medicare patients
1,583
Services billed
5,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj49$1,824,748
LumiganBimatoprost80$49,388
RestasisCyclosporine28$34,614
MieboPerfluorohexyloctane/Pf27$27,540
XiidraLifitegrast14$21,761
Prednisolone Acetate460$17,309
Cyclosporine16$17,025
ProlensaBromfenac Sodium48$16,941
CombiganBrimonidine Tartrate/Timolol33$13,990
Fluorometholone169$11,764
IlevroNepafenac32$11,732
Bromfenac Sodium47$8,901
Latanoprost590$8,418
MoxifloxacinMoxifloxacin Hcl263$8,244
Travoprost40$7,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$548$1,824,74849 claims
AbbVieLumigan, Restasis, Combigan$107,043$97,992141 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$20$49,30241 claims
NovartisIlevro$51,086$11,73232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Mount Dora

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →